Background The spectrum of nonalcoholic fatty liver disease (NAFLD) describes disease conditions deteriorating from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) to cirrhosis (CIR) to hepatocellular carcinoma (HCC). From a molecular and biochemical perspective, our understanding of the etiology of this disease is limited by the broad spectrum of disease presentations, the lack of a thorough understanding of the factors contributing to disease susceptibility, and ethical concerns related to repeat sampling of the liver. To better understand the factors associated with disease progression, we investigated by next-generation RNA sequencing the altered expression of microRNAs (miRNAs) in liver biopsies of class III obese subjects (body mass index C40 kg/m 2 ) biopsied at the time of elective bariatric surgery. Methods Clinical characteristics and unbiased RNA expression profiles for 233 miRs, 313 transfer RNAs (tRNAs), and 392 miscellaneous small RNAs (snoRNAs, snRNAs, rRNAs) were compared among 36 liver biopsy specimens stratified by disease severity.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is a condition of increased lipid deposition in the liver which is associated with obesity, insulin resistance, hepatic dysfunction, and other features of the metabolic syndrome. By the year 2020, NAFLD is expected to be the leading indication for liver transplantation [1] . Nonalcoholic steatohepatitis (NASH) is a particularly worrisome stage of NAFLD, characterized by liver inflammation and hepatocellular damage on a background of simple steatosis [2] . NASH occurs in *40 % of class III obese subjects (body mass index C40 kg/m 2 ) by mechanisms that are not entirely understood [3] . If left untreated, NASH can progress to irreversible liver damage in the form of cirrhosis and hepatocellular carcinoma (HCC). NASH is discriminated from NAFL by the additional presence of liver inflammation and hepatocyte damage (ballooning) identified in a liver biopsy. Our data from *200 bariatric subjects (BMI C 35 kg/m 2 ) place the incidence of NAFL (hepatic fat content [10 %) at approximately 80 %, with 40 % having SS and 40 % displaying NASH.
Many eukaryotic organisms have evolved miRNAs, which are single-stranded noncoding RNAs of 19-25 nucleotides, as a mechanism to modulate translation. Transcription of miRNA genes by RNA polymerase II (RNA pol II) results in the production of monocistronic, bicistronic, and polycistronic miRNA precursors. Transcription patterns of miRNAs during differentiation, fibrosis, and insulin resistance are tightly regulated. Once fully processed, miRNAs regulate gene expression through post-transcriptional mechanisms that include blocking the translation or promoting the cleavage of specific target mRNAs or targeting promoter regions. miRNAs play critical roles in lipid metabolism, apoptosis, inflammation, as well as cell growth and differentiation in both endocrine and paracrine manners on multiple tissues [4] . The regulatory role of miRNAs is suggested by unique miRNA signatures for different tissues.
It has been shown that miRNA sequencing is capable of capturing all species of small RNAs, including tRNA, snoRNAs, snRNA, and rRNAs [5, 6] . tRNAs are often the primary product of miRNA sequencing, with abundances exceeding those of miRNAs. tRNAs have been found to be associated with various diseases, including cancer [7] [8] [9] , diabetes [10] [11] [12] , and mitochondrial disorders [13] [14] [15] . The potential functionality of tRNAs and other species of small RNAs with NAFLD remains largely unexplored. We hypothesized that certain small RNAs are associated with the severity of NAFLD. To test this hypothesis, we applied an unbiased miRNA sequencing and bioinformatics strategy to liver biopsy samples from 36 NAFLD patients.
Methods

Human subjects
Class III obese subjects who were scheduled for elective bariatric surgery and between 26 and 59 years old were recruited from the Center for Surgical Weight Loss and the Endocrinology Clinics at Vanderbilt University Medical Center to participate in this study. Exclusion criteria included presence of viral hepatitis, autoimmune hepatitis, hemochromatosis, significant alcohol use, intercurrent infections, and active cancer diagnosis within the previous 5 years. Subjects gave their informed written consent before participating in this study, which was approved by the Internal Review Board of Vanderbilt University (090657) and registered at ClinicalTrials.gov (NCT00983463). All studies were conducted in accordance with the NIH and institutional guidelines for human subject research. The study protocol conformed to the ethical guidelines of the 2013 Declaration of Helsinki, as reflected in a priori approval by Vanderbilt University Medical School. All subjects, in preparation for bariatric surgery, were fasted. Wedge liver biopsies of the left lateral lobule were collected by harmonic scalpel at the time of laparoscopic bariatric surgery (Roux-en-Y gastric bypass). Samples were blotted free of blood, dissected free of unusable tissue, and immediately frozen in liquid nitrogen prior to storage at -80°C.
Scoring of liver specimen
The presence of steatosis, ballooning, fibrosis, inflammation, and iron were determined by a pathologist using two independent histology specimens. Samples were categorized using the NAS scoring criteria [16] : steatosis (\5 %, 0; 5 to 33 %, 1; 34 to 66 %, 2; [66 %, 3), ballooning degeneration (none, 0; few, 1; many, 2), lobular inflammation (none, 0, \2 foci/200 HPF, 1; 2-4 foci/200 HPF, 2; [4 foci/200 HPF, 3), fibrosis (none, 0; zones 1-3, 1; zone 3 and periportal, 2; bridging, 3; cirrhosis, 4). Four cohorts of subjects were established: those with normal livers (n = 10), NAFL (n = 12), NASH (n = 11), and cirrhosis (n = 3), based on histology (Table S1 in the Electronic supplementary material, ESM).
RNA isolation and sequencing
Total RNA from liver biopsies were isolated using a mir-CURY miRNA isolation kit (Exiqon, Grand Island, NY, USA), per the manufacturer's instructions. The Exiqon miRNA isolation kit was used because a previous study noted that this RNA isolation kit performed better than the TRIzol miRNA isolation kit [17] . Sequencing libraries were prepared using the TruSeq Small RNA sample preparation kit (Illumina, San Diego, CA, USA). The small RNA protocol specifically ligates RNA adapters to mature miRNAs that have a 5 0 -phosphate and 3 0 -hydroxyl group resulting from enzymatic cleavage by RNA processing enzymes like Dicer. In the first step, RNA adapters were ligated onto each end of the RNA molecule, and a reverse transcription reaction was used to create single-stranded cDNA. This cDNA was then PCR amplified with a universal primer and a second primer containing one of 48 uniquely indexed tags to allow multiplexing. Size selection of the cDNA constructs were performed using a 3 % gel cassette on the Pippin Prep (Sage Sciences, Beverly, MA, USA) in order to reduce the library to mature miRNAs and other regulatory RNAs in the 20-30 bp size range. The resulting cDNA libraries then underwent a quality check with the Bioanalyzer HS DNA assay (Agilent, Santa Clara, CA, USA) to confirm the final library size and using the Agilent Mx3005P qPCR machine with the KAPA library quantification kit (Illumina) to determine concentration. A 2-nM stock was created, and samples were pooled by molarity for multiplexing. From the pool, 10 pM were loaded into each well for the flow cell on the Illumina cBot for cluster generation. miRNA sequencing was performed using an Illumina HiSeq 2500 utilizing v3 chemistry and HTA 1.8. The raw sequencing reads were processed through CASAVA-1.8.2 for FASTQ conversion and demultiplexing.
Data processing
We implemented a custom analysis pipeline [18] for small RNA sequencing data processing. We used Cutadapt [19] to trim 3 0 adapters for raw reads. Quality control on the raw data was performed using QC3 [20] . All reads with lengths of less than 16 were discarded. The adaptor-trimmed reads were formatted into a nonredundant FASTQ file in which the read sequence and copy number was recorded for each unique tag. The usable unique reads were mapped to the whole genome using Bowtie1 [21] , with only one mismatch allowed. In addition, our pipeline takes into consideration nontemplated additions [22] [23] [24] [25] at the 3 0 end of the miRNA during alignment, which results in more accurate miRNA expression quantification. The tRNA database was prepared by combining the latest UCSC tRNA database GtRNAdb [26] with the tRNA loci of mitochondria from the Ensembl database [27] . The reads mapped with tRNA loci were used not only for tRNA quantification but also for tRNA mapping position coverage analysis. Small RNAs were divided into three major categories: miRNAs, tRNAs, and other small RNAs (including lincRNAs, snoRNAs, snRNAs, rRNAs, and miscellaneous RNAs in the Ensembl database). Expression data quality control was performed using MultiRankSeq [28] . The elastic net method [29] was used to select a panel of small RNAs that together explain a large part of the variation in NAFLD progression. Differential RNA expression analysis was conducted using DESeq2 [30] . Samples were classified by liver histology into four conditions: normal, NAFL, NASH, and cirrhosis. Ordinal regression with the elastic net method was used to identify the small RNA that can best explain the variation in liver conditions. The elastic net method is a variation of the Lasso regression method [31] , a technique for L1-norm regularization, which has been used for variable selection (or dimensional reduction) in problems where the number of features p exceeds the number of cases N, in order to produce parsimonious and interpretable models. The elastic net method provides variable selection in the p ) N case without being severely limited by the sample size. This method greatly improves performance in the case of highly correlated predictor variables (which we expect to have in the clinical data) through the identification of significant highly correlated groups of phenotypes that contribute most to the variation in the data. The R package glmnetcr was developed for elastic net analysis and was used to evaluate the overall association of the small RNA and the treatment response. Because an ordinal regression model does not produce an adjusted R 2 , McFadden's R 2 [32] was computed as a surrogate to estimate the overall variation explained. McFadden's R 2 is usually less than the adjusted R 2 ; a value between 0.2 and 0.4 is considered a well-fitted model. Trend analysis of small RNA expression across the four liver conditions (normal ? NAFL ? NASH ? cirrhosis) was conducted using a Mann-Kendall trend test [33] . Due to the lack of a functional database for tRNA and other small RNAs, we only conducted functional analysis on candidate miRNAs using Ingenuity Pathway Analysis (IPA).
Additional analyses were performed on the three candidate miRNAs using HCC patients from The Cancer Genome Atlas (TCGA). TCGA is a comprehensive and coordinated consortium project by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies. TCGA contains miRNA expression data from 377 HCC patients with clinical information. We performed correlation analysis between the three candidate miRNAs and various clinical variables, including pathological stage, fibrosis stage, etc.
Because the majority of our NFALD patients were female, we only conducted the analysis on female HCC patients who were age-matched to our NFALD patients.
RT-PCR
Total RNA was reverse transcribed using the Universal cDNA Synthesis Kit II (Exiqon, Woburn, MA, USA) per the manufacturer's protocol, utilizing the UniSp6 RNA Spike-In control primer set. miRNAs were amplified using LNA technology with the hsa-miR-301a, hsa-miR-34a-5p, and hsa-miR-3375 primers using Exilent SYBR green reagents (Exiqon). Amplificants were analyzed for distinct melting curves, and it was checked that T m was within known specifications for the assay. RT-PCR data were analyzed using the 2 ÀDDC T method and normalized to 18S [34] . Spearman's correlation between the RT-PCR data and the miRNA sequencing gene expression data was computed to evaluate the accuracy of miRNA sequencing. Table 1 shows physical, anthropometric, and biochemical measurements of all subjects in the study. All class III obese [body mass index (BMI) C40 kg/m 2 ] subjects were female, and our four cohorts (''Normal,'' ''NAFL,'' ''NASH,'' and ''Cirrhosis,'' as defined by NAFLD activity scoring [16] ) were composed of similar ethnicities (almost exclusively Caucasian), body weights, and BMIs. Total RNA extracted from liver biopsy tissues obtained intraoperatively during elective bariatric surgery was subjected to next-generation sequencing. As reported in previous studies, NASH subjects were slightly older [35] . NASH subjects also displayed significantly elevated levels of alkaline phosphatase without showing significant differences in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels.
Results
The sequencing data were thoroughly quality controlled, and the detailed alignment statistics can be found in Table S1 in the ESM. The overall mapping rate of all samples was 67 %. In small RNA sequencing, the majority of the alignments will be to tRNA rather than miRNA. In our data, on average, 4 % of all mapped reads were mapped to miRNA. This is consistent with previous findings on miRNA sequencing [36] . On average, 80 % of all mapped reads were mapped to tRNAs and the rest were mapped to other RNAs, including snoRNA, tRNA, snRNA, rRNA, etc. After thorough quality control, we identified 233 miRNAs, 313 tRNAs, and 393 other small RNAs that were suitable for additional analyses.
miRNA expression differences
Differential expression analyses were performed for three major types of small RNA: miRNA, tRNA, and other small RNAs. Four cohort comparisons were made using DESeq2 [30] , a robust methodology for differential analysis of count data. We compared expression profiles (miRNA, tRNA, or other small RNAs) for specimens spanning the spectrum of NAFLD: (1) Cirrhosis vs Normal, (2) Cirrhosis ? NASH vs Normal, (3) NASH vs Cirrhosis, and (4) NASH vs NAFL. For miRNA and tRNA, we found the greatest abundance differentials between the Cirrhosis and Normal cohorts. The smallest abundance differentials were between NASH and NAFL, where no miRNAs were found to be significantly different after adjusting the P value for multiple comparisons. Four miRNAs (miR-10b-5p, miR-143-3p, miR-301a-3p, and miR-34a-5p) were increased while three miRNAs were decreased (miR-181a-5p, miR-28-5p, and miR-375) in Cirrhosis vs Normal. Of these, the expression levels of miR-301a-3p, miR-34a-5p, and miR-375, along with three others (miR-122-3p, miR-1248, and miR-301a-3p), were also significantly different when a Cirrhosis ? NASH vs Normal comparison was made. There were no miRNAs that were significantly different between NASH and NAFL, and only miR-375 was different (decreased) upon comparing NASH vs Cirrhosis. A summary of the results of differential expression analysis can be found in Table 2 . The complete results from the differential expression analyses for miRNA can be found in Table S2 in the ESM. 
tRNA expression differences
In a Cirrhosis vs Normal cohort comparison, we found that there was significant differential expression of 23 tRNAs with Cirrhosis, most notably tRNA7, tRNA9, tRNA11, and tRNA13 for lysine (anticodon CTT), tRNA10, tRNA12, tRNA38, and tRNA45 for aspartate (anticodon GTC), and tRNA3, tRNA5, tRNA11, and tRNA20 for glutamate (anticodon TTC). The majority (15) of these tRNAs were downregulated in Cirrhosis. Notably, one mitochondrial tRNA2 for valine was significantly upregulated. The downregulation of tRNA3 and tRNA11 for GluTTC also distinguished Cirrhosis from NASH. Two mitochondrial tRNAs, tRNA11-TY and rTNA18-TS2 (encoding mitochondrial tRNAs for the amino acids tyrosine and serine, respectively), were significantly upregulated. The complete results from the differential expression analyses for tRNA can be found in Table S3 in the ESM. Seven AAG tRNAs for leucine and two RNAs for aspartate (codon GTC) fell just short of being significantly reduced (P C0.054 and B0.056) in Cirrhosis ? NASH vs Normal.
Other small RNAs
For other small RNAs, the largest differences again were found for Cirrhosis ? NASH vs Normal. Two small Y RNAs (ENSG00000252316 and ENSG00000201778)-rare types of small noncoding RNAs that are components of Ro ribonucleoproteins-were found to be downregulated when NASH was compared to Cirrhosis. The complete results of the differential expression analyses for other small RNAs can be found in Table S4 in the ESM.
miRNA trend analysis and validation
Trend analyses using the Mann-Kendall trend test identified many monotonically increasing and decreasing small RNAs: 16 increasing and 37 decreasing miRNAs; 35 increasing and 31 decreasing tRNAs; 35 increasing and 32 decreasing other small RNAs. A summary of the trend analyses can be viewed in Table S5 in the ESM, and detailed trend analyses for miRNA, tRNA, and other small RNAs can be viewed in Tables S6, S7 , and S8 in the ESM, respectively. We conducted functional analysis using the 16 increasing and 37 decreasing miRNAs using Ingenuity Pathway Analysis, and identified several hepatotoxicities, including hepatocellular carcinoma, liver damage, and liver steatosis (see Table S9 in the ESM). These results suggest that the linear trend for changes in miRNA expression across the four liver conditions is closely related to hepatotoxicity. The elastic net method with ordinal regression was applied to identify the subset of small RNAs that can explain the most variation in the liver conditions. Elastic net identified three miRNAs (hsa-miR-301a-3p, hsa-miR-34a-5p, and hsa-miR-375) but no tRNAs or other small RNAs. This suggests that the roles of tRNAs and other small RNAs in NAFLD progression might not be as important as that of miRNAs. The three selected miRNAs were further fitted into an ordinal cumulative link model and showed reasonable significance (hsa-miR-301a-3p P = 0.09, hsa-miR34a-5p P = 0.06, hsa-miR-375 P = 0.13) ( Table 3 ). McFadden's R 2 was computed to be 0.31, which suggests that at least 31 % of the variation within the four liver conditions can be explained by the three miRNAs. It is known that McFadden's R 2 usually underestimates the true variability explained, so it might be higher than 31 %.
Further functional analyses of these three miRNA were conducted manually. All three miRNAs were also identified in the trend analyses (Fig. 1) . The first miRNA, miR301a-3p, which was also found to monotonically increase as the liver condition progressed from normal to cirrhosis in the trend analysis, is upregulated in HCC according to multiple studies [37] [38] [39] [40] [41] . The second miRNA, miR-34a-5p, which was found to monotonically increase in the trend analysis, was upregulated in hepatic fibrosis in rat [42] and mouse [43] . The third miRNA, miR-375, which was found to monotonically decrease in trend analysis, is downregulated in HCC [44, 45] . The results of the functional analysis are in close concordance with the results from trend analysis, suggesting that these three miRNAs may be used as biomarkers to predict liver condition.
RT-PCR validation of miR-34a-5p, miR-375, and miR-301-5p was carried out on 14 samples for which remaining RNA was available (Normal, n = 5; NAFL, n = 5; NASH, n = 4). All three miRNAs were observed to have the same general patterns of gene expression as those observed with RNA-seq (Fig. 1b) .
Patients with NAFLD are at an increased risk for HCC [46] [47] [48] . We compared our miRNA expression pattern with miRNA expression profiles from hepatocellular carcinoma (HCC) datasets from TCGA; miRNA sequencing data of 110 HCC samples (female) from various HCC stages (stage I N = 49, average age = 63.6, stage II N = 27, average age = 64.7, stage III and IV N = 34, average age = 53.7) were analyzed. Furthermore, in TCGA, miR-34a was reported without distinction between its 5p and 3p forms. We found that, out of the three candidate miRNAs, two (miR-301a-3p and miR-375) expressed the same expression pattern (on a log2 scale) as HCC progressed from early stage to late stage (Fig. 1c) . The expression pattern of miR-301a-3p in our specimen staged for progressive NAFLD was nearly identical to that of has-miR-301a in TCGA HCC data. These results demonstrate a persistence of this specific pattern of miRNA expression in more advanced forms of liver disease such as HCC. Additional correlation analyses were performed between the three candidate miRNAs and 18 clinical variables such as fibrosis stage and alpha-fetoprotein test. No significant correlation was detected (Table S10 in the ESM).
Discussion
In this study, we measured relative miRNA, tRNA, and other small RNA abundance levels in liver biopsy tissues from class III obese human subjects (BMI C 40 kg/m 2 ) using an unbiased next-generation RNA sequencing and bioinformatics strategy. We found that the levels of three miRNAs were significantly correlated with NAFLD severity, suggesting that these miRNAs may contribute to the progression of NAFLD. In addition, several tRNAs and other small RNAs identified in our analysis exhibited differential abundance patterns that were specific for a certain stage of NAFLD. These differences afford new insight into the pathophysiology of NAFLD progression.
The differential abundance of human miRNAs with NAFLD has been examined most extensively in human serum. Pirola et al. identified significant fold differences in serum levels of miR-122 (a 7.2-fold change in NASH vs controls and a 3.1-fold change in NASH vs simple steatosis) and miR-102 (a 4.4-fold change in NASH vs controls) [49] . Cermelli et al. used targeted Taqman miRNA qRT-PCR to show increased serum levels of miR-122, miR-34a, and miR-16 in NAFLD (NAFLD activity score; NAS B 4) and NASH (NAS C 5) patients compared to controls [50] . In a cohort of low BMI (B26.2 kg/m 2 ) with ultrasound-diagnosed NAFLD, Yamada et al. identified increased serum abundances of miR-21, miR-34a, miR-122, and miR-451 relative to controls [51] . Interestingly, only the elevations in miR-34a and miR-122 were significant in both men and women. Tan et al. identified miR-122-5p, miR-1290, miR-27b-3p, and miR-192-5p as a panel of high diagnostic accuracy for NAFLD in a population with low BMI (25.2 kg/m 2 ) and low NAS scores [52] . Similarly, Celikbilek et al. quantified 9 miRNAs in serum of histologically proven NAFLD and moderately obese (n = 20; BMI 31.9 kg/m 2 ) subjects as well as healthy age-matched controls (n = 20; 27.3 kg/m 2 ) [53] . They observed significantly decreased expression of miR-197, miR-146b, miR-181d, and miR-99a in the NAFLD subjects.
In the current study, hepatic levels of miR-301a-3p and miR-34a-5p were monotonically increased and miR-375 was monotonically decreased from simple steatosis to NASH to cirrhosis. While some studies have linked miRNA dysregulation to the pathogenesis of NAFLD by profiling adipose tissue as a surrogate for difficult-to-obtain liver tissue [54, 55] , our study is one of the few to examine hepatic miRNA expression differences in biopsy-staged NAFLD. Cheung et al. used lParaflo to quantify the differential expression of 474 microRNAs in NASH (BMI 35 kg/m 2 ) vs controls (BMI 39.5 kg/m 2 ) [4] . Forty-six miRNAs were differentially expressed in subjects with NASH, with half overexpressed and half underexpressed in the advanced form of the disease. miR-34a-5p was among the microRNAs to be significantly overexpressed, and miR-375 was among those to be significantly underexpressed with NASH; interestingly, miR-301a did not change. Other results consistent with the altered pattern of microRNAs we detected come from studies of hepatocellular carcinoma [56, 57] and NAFLD [58] , where differential expression of miR-34a seems to play a contributing role in disease progression, possibly through a SIRT1-AMPK-HMGCR mechanism [59] . However, the extent to which these profiles are concordant with hepatic gene miRNA expression is unknown.
The molecular mechanisms leading to HCC are not well understood, but multiple risk factors, including obesity, insulin resistance, and hepatic steatosis, have been proposed to play a mediating role. While HCC generally arises on a background of cirrhosis, NAFLD without cirrhosis is an emergent and independent risk factor for hepatocellular carcinoma [60] . Aberrant miRNA expression patterns borne of some or all of these risk factors may underlie NAFLD progression and potentiate the development of HCC in some individuals. Increased expression of miR301a and downregulation of the homeobox gene Gax was associated with metastasis [61] . Downregulation of miR-375 altered ATG7 expression and inhibited mitochondrial autophagy in HCC cells [62] . Decreased expression of miR-34a regulated by TGF-b targeted c-MET [63] and CCL22 [64] . These and other findings strongly suggest a role for these miRNAs in both NAFLD and HCC progression.
While there are several known and predicted biological targets of miR-34a-5p, miR-301-3p, and miR-375, two genes, including DNAJC16 (DNAJ homolog, subfamily C, member 16) and TNRC6B (trinucleotide repeat containing 6B), exhibit 8-and 7-mer seed regions matching all three of these miRNAs (TargetScan; http://www.targetscan.org). Another 48 targets are predicted to pair with miR-34a and miR-301a, which exhibited similar monotonic increases in expression with NAFLD progression. Targets of miR-375 in the liver include astrocyte elevated gene-1 (AEG-1) [65] and yes-associated protein (YAP) [66] ; the former plays a role in mediating steatosis [67] and the latter is a mediator of hepatic proliferation and differentiation [68] .
In conclusion, this study describes a novel pattern of miRNA expression in biopsy-staged NAFLD characterized by increased miR-301a-3p and miR-34a-5p and decreased miR-375 with worsening liver histology. The pattern of increased miR-301a-3p and decreased miR-375 abundances was additionally present in early-to late-stage HCC, suggesting that these miRNAs are important modulators of liver disease progression. Alone, or in tandem with other clinical findings, these miRNAs inform on NAFLD severity and may serve as effective targets to modulate liver function for therapeutic benefit or prevent NAFLD progression.
